Explainability and white box in drug discovery

dc.authoridKirboga, Kevser Kubra/0000-0002-2917-8860
dc.contributor.authorKirboga, Kevser Kubra
dc.contributor.authorAbbasi, Sumra
dc.contributor.authorKucuksille, Ecir Ugur
dc.date.accessioned2025-05-20T18:56:16Z
dc.date.issued2023
dc.departmentBilecik Şeyh Edebali Üniversitesi
dc.description.abstractRecently, artificial intelligence (AI) techniques have been increasingly used to overcome the challenges in drug discovery. Although traditional AI techniques generally have high accuracy rates, there may be difficulties in explaining the decision process and patterns. This can create difficulties in understanding and making sense of the outputs of algorithms used in drug discovery. Therefore, using explainable AI (XAI) techniques, the causes and consequences of the decision process are better understood. This can help further improve the drug discovery process and make the right decisions. To address this issue, Explainable Artificial Intelligence (XAI) emerged as a process and method that securely captures the results and outputs of machine learning (ML) and deep learning (DL) algorithms. Using techniques such as SHAP (SHApley Additive ExPlanations) and LIME (Locally Interpretable Model-Independent Explanations) has made the drug targeting phase clearer and more understandable. XAI methods are expected to reduce time and cost in future computational drug discovery studies. This review provides a comprehensive overview of XAI-based drug discovery and development prediction. XAI mechanisms to increase confidence in AI and modeling methods. The limitations and future directions of XAI in drug discovery are also discussed.
dc.description.sponsorshipWiley, Republic of Turkey [2023]
dc.description.sponsorshipThis study was supported by the Read&Publish agreement between TUEBITAK ULAKBIM and Wiley, Republic of Turkey (2023).
dc.identifier.doi10.1111/cbdd.14262
dc.identifier.endpage233
dc.identifier.issn1747-0277
dc.identifier.issn1747-0285
dc.identifier.issue1
dc.identifier.pmid37105727
dc.identifier.scopus2-s2.0-85158067657
dc.identifier.scopusqualityQ2
dc.identifier.startpage217
dc.identifier.urihttps://doi.org/10.1111/cbdd.14262
dc.identifier.urihttps://hdl.handle.net/11552/7660
dc.identifier.volume102
dc.identifier.wosWOS:000977185200001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWoS
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.indekslendigikaynakWoS - Science Citation Index Expanded
dc.language.isoen
dc.publisherWiley
dc.relation.ispartofChemical Biology & Drug Design
dc.relation.publicationcategoryDiğer
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250518
dc.subjectartificial intelligence
dc.subjectcomputational drug discovery
dc.subjectdrug development
dc.subjectexplainable artificial intelligence
dc.titleExplainability and white box in drug discovery
dc.typeReview

Dosyalar